The ATP Project (Antipsychotic-TEP-Psychosis)

Launched by UNIVERSITÉ DE SHERBROOKE · Oct 18, 2024

Keywords

ClinConnect Summary

The ATP Project is a clinical trial that aims to understand how antipsychotic medications affect the brain in young adults who have recently experienced their first episode of psychosis. The study will look at how these medications influence brain metabolism, which is how the brain uses energy. To do this, researchers will use a special type of brain scan called a PET scan, along with other tests to measure mental health and physical health factors over 4 to 6 weeks.

To participate in this trial, individuals aged 16 to 30 who have been admitted to a specific clinic in Estrie may be eligible if they are willing to start taking antipsychotic medication and can understand and sign a consent form in French or English. However, some people may not qualify, such as those who are pregnant, have had certain medical conditions, or have previously taken antipsychotics for extended periods. Participants can expect to undergo brain scans and complete various assessments during the study, which will help researchers learn more about the effects of these medications on mental health and brain function. The trial is not yet recruiting participants, so there will be more information available soon.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admission to the PEP clinic in Estrie, either outpatient or inpatient, according to the transdiagnostic PEP model.
• • Willingness to begin taking an AP (regardless of type and dose, or change in type and dose during the study).
• • Ability to read and express themselves in French or English.
• • Capable of understanding and signing consent.
• Exclusion Criteria:
• • Pregnancy, childbirth in the last 6 months, or breastfeeding.
• • Presence of a metallic object in the body that is incompatible with MRI.
• • Any use of APs for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription).
• • The following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal.
• • Type 1 diabetes.
• • Uncontrolled acute suicidal ideation.
• • Other conditions that could interfere with participation according to the judgment of the qualified physician.